Pray , Tell;;;;; For exactly what reasons do you continue to bring this myriad of complaints to me? Is this indirect approach not futile? I am much impressed with the MSTX platform. As far as I can read, MSTX is doing exactly what they have committed to do. I would think it strategically and fiscally catastrophic, to redirect the MSTX programming platform; from the traumas involving blood and vasculature, resulting from vascular occlusion; right while the phase 3 trials of the EPIC study are coming to fullest fruition, and conclusion. The funding, and all systems' coordinations, are based on this specific effort(EPIC Study), and other concurrent studies. The entire system can not be translated to a genetics repair platform, it would appear.
Why you question the administration's capacity, as regards product movement, is entirely puzzling for me. Are you not relying on recent reports of BSAF chemical industries collaborations? DO you desire the administration to move ahead of FDA sanctioning of any MSTX drug or product? Exactly what would you propose at this phase, as I am curious now.? The FDA is not going to pretend that a less than complete drug study, is complete, and that the drug is ready for human consumption/treatment; before these studies can be formally completed and reviewed..? Rollout of this new and patented drug, MST 188, (or any other drug in testing) would be the next phase, post Phase 3 trials/ reviews. How can the admin. possibly be judged for it's performance in mass product manufacturing, marketing or distribution while at this trial 3 phase of the EPIC study? Please remember past, present and future committed coordinations with BSAF.
And, no, all of this is not presently meant to CURE sickle cell disease. Possibly there is confusion therein as you keep discussing that issue. That would fall under a structure of decades long studies, building on a platform focused specifically on the genetics of inherited diseases. Obviously, this is divergent from the EPIC study,IMO. (There may be companies or universities which have decades of research and discovery based on genetic disease study, which are more closely relevant to your desires.) Those cure oriented scientists are primarily specialized in genetic theory, disease inheritance, mutation, etc. They are not cutting edge scientists in sickle cell vascular trauma, pediatric occlusive pain, and drug therapy/ interactions. Needless to say, we would all join in on the desire to see a cure discovery for sickle cell disease. But the trauma and pain of vascular occlusive events are severe, and need to be dealt with today, using far more expansive and successful treatments.
This (MSTX) company's specilized science/research and funding are directed at hematologogic and vascular research/discovery/drug therapies relative to vascular occlusive events, including SCD. Possibly you might be pleased to read the presentation material to be introduced nationally and internationally, in early Dec., 2015, at Orlando, so that you might better appreciate what the MSTX scientists ARE currently unraveling.
There is no one here who can assist you with your present concerns about company communications. The most direct line of communication would be from you to MSTX. It is worthy of consideration that numerous reports are currently being made publicly available, ( re: what this company is introducing internationally) re: MST 188 benefits/ function.
Remember, it is strictly illegal for a company to publically divulge the ongoing results of an FDA approved, double blind study, prior to study completion, and the final FDA review. However, the company has kept us abreast of where it is, in receiving approved subjects /participants for the Phase 3 trial of EPIC SCD study, in more than 70 international research/test sites. Good luck in your endeavor. There would be everything right in your presenting your ideas to the MSTX board as an active or past investor. All stated here is strictly IMO.
